ImmunoGen

ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

ImmunoGen reports successful 2022, eyes growth opportunities in 2023

ImmunoGen's strong 2022 performance, strategic partnerships, and positive market feedback set the stage for continued growth. While facing challenges in expenses and revenue targets, the company is well-positioned to capitalize on upcoming milestones and revenue streams.

ImmunoGen reports robust Q1 revenue, eyes growth opportunities

ImmunoGen's Q1 2023 earnings call showcased strong revenue performance
ELAHERE's market uptake and physician feedback remain positive
Operational challenges include increased expenses and regulatory evolution
Opportunities lie in resistance mechanisms study and program expansions

ImmunoGen reports strong Q2 revenue, focuses on Elahere growth

ImmunoGen's Q2 performance showed revenue growth and strong cash position
Elahere's success in trials and sales presents growth opportunities
Challenges include managing expenses and competition in the market
Opportunities lie in R&D investments, market expansion, and guideline updates

ImmunoGen reports robust Q3 earnings, eyes global expansion opportunities

ImmunoGen's strong financial performance and ELAHERE's success highlight a promising quarter.
Challenges include late responses in data sets and understanding the FR alpha and CDH overlap.
Opportunities lie in providing future revenue guidance, expanding globally, and exploring new molecules.
Overall, ImmunoGen's focus on ELAHERE's growth and strategic initiatives position it well for the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ImmunoGen, Inc. engages in the research and development of antibody-based anticancer therapeutics in the United States. The company develops therapeutics for the treatment of cancer using its Targeted Antibody Payload (TAP) technology, which uses antibodies to deliver a potent cytotoxic agent. Its products include Trastuzumab-DM1, a Phase II clinical trial product for the treatment of metastatic breast cancer; IMGN901, a Phase I clinical trial product to treat hematological malignancies, including multiple myeloma, small-cell lung cancer, Merkel cell carcinoma, and other cancers of neuroendocrine origin; SAR3419, a Phase I clinical trial product for the treatment of B-cell hematological malignancies, including non-Hodgkin's lymphoma; and IMGN388 and BIIB015, which are in Phase I clinical trials for the treatment of solid tumors. The company's products also comprise BT-062, a Phase I clinical trial product targeting multiple myeloma; SAR566658, a preclinical trail product for the treatment of breast, ovarian, and other solid tumors; SAR650984, a preclinical trail product to treat hematological malignancies; and TAP and other compounds. It has licensing or collaboration agreements with sanofi-aventis; Genentech, Inc.; Biotest AG; Bayer HealthCare AG; Biogen Idec; Amgen, Inc.; Centocor, Inc.; Cytovance Biologics LLC; Laureate Pharma, Inc.; BioInvent International AB; Diosynth RTP, Inc.; and Societa Italiana Corticosteroidi S.r.l. ImmunoGen was founded in 1981 and is headquartered in Waltham, Massachusetts.

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Results from the Phase 3 MIRASOL Trial Selected as Late-Breaking Presentation for ASCO 2023 Annual Meeting.

ImmunoGen Announces Results from the Phase 3 MIRASOL Trial Selected as Late-Breaking Presentation for ASCO 2023 Annual Meeting

Commercial-state biotechnology company ImmunoGen Inc. NASDAQ: IMGN shares more than doubled on phase 3 clinical trial results. Its ovarian cancer drug Elahere shows statistical improvements for progression-free survival (PFS) and overall survival (OS) for patients in a MIRASOL late-stage study.

ImmunoGen Nearly Triples on Ovarian Cancer Drug Phase 3 Results

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the pricing of an underwritten public offering of 26,000,000 shares of its common stock at a price of $12.50 per share, before underwriting discounts and commissions. The offering is expected to close on or about May 9, 2023, subject to satisfaction of customary closing conditions. ImmunoGen also granted the underwriters.

ImmunoGen Announces Pricing of Upsized Public Offering of Common Stock

ImmunoGen's Elahere (mirvetuximab soravtansine-gynx) has shown positive results in a confirmatory trial for platinum-resistant ovarian cancer, boosting the company's stock by over 130%. ImmunoGen's Q1 2023 revenues were primarily driven by Elahere sales, totaling $49.9 million. However, its market potential is currently confined to later-stage treatment of platinum-resistant ovarian cancer.

ImmunoGen's Elahere Breakthrough Offers Hope For Patients And Investors Alike

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Proposed Public Offering of Common Stock.

ImmunoGen Announces Proposed Public Offering of Common Stock

ImmunoGen Inc stock more than doubled after the company shared positive topline data from the Phase 3 confirmatory MIRASOL trial evaluating the safety and effectiveness of its experimental ovarian cancer drug Elahere. The study compared Elahere with chemo in patients with platinum-resistant ovarian cancer, who have received one to three prior lines of therapy.

ImmunoGen stock price doubles after ovarian cancer candidate Elahere aces phase 3 study

The company said it anticipates asking for full approval of Elahere from the FDA. The drug was granted accelerated approval in November to treat advanced ovarian cancer.

Why ImmunoGen Stock Is Soaring Wednesday

The mean of analysts' price targets for ImmunoGen (IMGN) points to a 101.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See a 101.92% Upside in ImmunoGen (IMGN): Can the Stock Really Move This High?

ImmunoGen (NASDAQ: IMGN ) stock is rising higher on Wednesday after the company released results from a Phase 3 trial for treating ovarian cancer. According to a press release, the company reported positive top-line data from its clinical trial of Elahere.

Why Is ImmunoGen (IMGN) Stock Up 125% Today?

Shares of Immunogen Inc. IMGN blasted 121.2% higher on heavy volume toward a five-year high in premarket trading Wednesday, after the biopharmaceutical company revealed positive data from a late-stage trial of its treatment for ovarian cancer. Trading volume spiked up to 12.2 million shares, compared with the full-day average of about 3.5 million shares.

Immunogen stock more than doubles on heavy volume after positive trial data ovarian cancer treatment

Eli Lilly

Markets were waiting to see what the Federal Reserve will do with interest rates later today. Eli Lilly announced favorable trial results for its Alzheimer's treatment.

Good News for Patients Is Lifting These 2 Biopharma Stocks

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced positive top-line data from the Phase 3 confirmatory MIRASOL trial (GOG 3045/ENGOT OV-55) evaluating the safety and efficacy of ELAHERE® (mirvetuximab soravtansine-gynx) compared to chemotherapy in patients with folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer who have received one to three prior lin.

ELAHERE® Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRα-Positive Platinum-Resistant Ovarian Cancer

ImmunoGen (IMGN) reports impressive Q1 earnings results on strong adoption of sole-marketed drug Elahere. The company raises financial guidance for 2023.

ImmunoGen (IMGN) Q1 Earnings Beat, Elahere Uptake Encouraging

ImmunoGen Inc shares rocketed higher Friday after the company's first quarter sales impressed investors.  The Massachusetts-based company posted revenue of $49.9 million, including $29.5 million of net product revenues from sales of its ovarian cancer drug ELAHERE.

ImmunoGen shares pop on 1Q sales of ovarian cancer drug

ImmunoGen's ovarian cancer therapy, Elahere, has had a strong launch. The company increased its revenue guidance for 2023.

Why Shares of ImmunoGen Jumped Friday

ImmunoGen (IMGN) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.10 per share a year ago.

ImmunoGen (IMGN) Reports Q1 Loss, Tops Revenue Estimates

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended March 31, 2023. “With a strong first full quarter of sales and continued momentum in FRα testing and market access, we have started the year making great strides towards establishing ELAHERE as the standard of care for FRα-positive ovaria.

ImmunoGen Reports Recent Progress and First Quarter 2023 Financial Results

Cosmos Holdings

Evolv Technologies Holdings

Terran Orbital Corp

Terawulf

5 penny stocks to watch. The post 5 Hot Penny Stocks To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Hot Penny Stocks To Watch Before Next Week

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Appoints Isabel Kalofonos as Senior Vice President and Chief Commercial Officer.

ImmunoGen Appoints Isabel Kalofonos as Senior Vice President and Chief Commercial Officer

ImmunoGen (IMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: ImmunoGen (IMGN) Q1 Earnings Expected to Decline

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, April 28, 2023 to discuss its first quarter 2023 operating results. Management will also provide a brief update on the business. CONFERENCE CALL INFORMATION To access the live call by phone, please register here.

ImmunoGen Announces Conference Call to Discuss Its First Quarter 2023 Operating Results

CRISPR Therapeutics

Vertex Pharmaceuticals

Vertex Pharmaceuticals recently completed regulatory requests for its blood disorder candidate, exa-cel. Exa-cel has what it takes to become a blockbuster over time.

Could This Move Make Vertex's Next Blockbuster Even Bigger?

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced it has entered into a term loan financing facility for up to $175 million with entities managed by Pharmakon Advisors, LP ("Pharmakon"). Proceeds from the agreement will strengthen ImmunoGen's balance sheet and provide the Company with additional capital to support its growth trajectory.

ImmunoGen Announces Non-Dilutive Term Loan Financing for Up to $175 Million with Pharmakon Advisors

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced final overall survival data and an evaluation of sequence of therapy in the pivotal SORAYA trial of mirvetuximab soravtansine in patients with folate receptor alpha-high platinum-resistant ovarian cancer who had been previously treated with bevacizumab will be presented by Dr.

ImmunoGen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial at SGO Annual Meeting

ImmunoGen, Inc. (NASDAQ:IMGN ) Q4 2022 Earnings Conference Call March 1, 2023 8:00 AM ET Company Participants Anabel Chan - Head, IR Mark Enyedy - President and CEO Anna Berkenblit - Chief Medical Officer Renee Lentini - Interim-CFO Todd Talarico - Interim-Chief Commercial Officer Conference Call Participants John Newman - Canaccord Genuity Michael Schmidt - Guggenheim Etzer Darout - BMO Capital Markets Boris Peaker - Cowen Andy Hsieh - William Blair Kelly Shi - Jefferies Asthika Goonewardene - Truist Daniel Wolle - JPMorgan Jonathan Chang - SVB Securities Peter Lawson - Barclays Operator Good morning, and welcome to ImmunoGen's Fourth Quarter and Full Year 2022 Financial and Operating Results Conference Call. Today's conference is being recorded.

News for ImmunoGen Stock (IMGN)